Abstract

Lung transplantation is a lifesaving therapy for people living with severe, life-threatening lung disease. The high mortality rate among patients awaiting transplantation is mainly due to the low percentage of lungs that are deemed acceptable for implantation. Thus, the current shortage of lung donors may be significantly reduced by implementing different therapeutic strategies which facilitate both organ preservation and recovery. Here, we studied whether the anti-inflammatory effect of human umbilical cord-derived mesenchymal stem cells (HUCPVCs) increases lung availability by improving organ preservation. We developed a lung preservation rat model that mimics the different stages by which donor organs must undergo before implantation. The therapeutic schema was as follows: cardiac arrest, warm ischemia (2 h at room temperature), cold ischemia (1.5 h at 4°C, with Perfadex), and normothermic lung perfusion with ventilation (Steen solution, 1 h). After 1 h of warm ischemia, HUCPVCs (1 × 106 cells) or vehicle was infused via the pulmonary artery. Physiologic data (pressure-volume curves) were acquired right after the cardiac arrest and at the end of the perfusion. Interestingly, although lung edema did not change among groups, lung compliance dropped to 34% in the HUCPVC-treated group, while the vehicle group showed a stronger reduction (69%, p < 0.0001). Histologic assessment demonstrated less overall inflammation in the HUCPVC-treated lungs. In addition, MPO activity, a neutrophil marker, was reduced by 41% compared with vehicle (p < 0.01). MSC therapy significantly decreased tissue oxidative damage by controlling reactive oxygen species production. Accordingly, catalase and superoxide dismutase enzyme activities remained at baseline levels. In conclusion, these results demonstrate that the anti-inflammatory effect of MSCs protects donor lungs against ischemic injury and postulates MSC therapy as a novel tool for organ preservation.

Highlights

  • Lung transplantation has become the standard treatment for end-stage respiratory diseases

  • We found that Human umbilical cord perivascular cells (HUCPVCs) protect donor lungs against ischemic injury by reducing oxidative damage and neutrophil extravasation into the lung tissue

  • We analyzed the immunophenotypic characteristics of the HUCPVCs used in this study to determine whether they conformed to the minimal criteria defining mesenchymal stem cell (MSC) [25]

Read more

Summary

Introduction

Lung transplantation has become the standard treatment for end-stage respiratory diseases. There is an increase in the number of annual lung transplants, the mortality on current waiting lists can be as high as 30% due to the shortage of organs available for transplantation [1, 2]. There is a low number of multiorgan brain death donors available. Only about 15% of lungs from these donors are suitable for transplantation as most of them are discarded due to injuries caused by brain death and/or poor donor management [3]. Transplant programs are usually very conservative in the selection of donor lungs to avoid severe complications associated with primary graft dysfunction (PGD). PGD is the end result of a series of injuries occurring in the donor organ from the time of death

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call